MicroRNAs as Biomarkers for Early Diagnosis, Prognosis, and Therapeutic Targeting of Ovarian Cancer

Table 2

Significant miRNAs with potential prognostic and diagnostic biomarkers.

Biomarker	Prognosis	Diagnosis	Tumor stages	Endpoint	Source	Ref.
miR-532-5p	Yes	No	Cell proliferation of ovarian neoplasms	OS	—	[242]
miR-200b	Yes	No	EMT and migration	OS	Ascitic fluid	[243, 244]
miR-193b	No	Yes	Lymph node metastasis	Poor survival	Tissue	[245]
miR-135a-3p	Yes	No	Cell proliferation of ovarian tumors	Decreased PFS	Peritoneal fluid	[246]
miR-125b	Yes	Yes	Lymph node involvement and distant metastasis	Decreased OS	Serum	[247]
miR-613	Yes	No	Lymph node involvement	Short PFS and OS	Tissue	[248]
miR-506	Yes	No	EMT	Decreased OS and PFS	Tissue	[249]
miR-205	Yes	Yes	Advanced stages III/IV	—	Plasma	[250]
miR-200c-3p, miR-346, miR-127-3p	No	Yes	Distant metastasis	—	Serum	[251]
miR-200c	No	Yes	Stage I	OS and PFS	Tissue	[252]
miR-27a and miR-23a	Yes	No	Stages I-IV	OS, RFS, and short PFS (miR-27a)	Serum	[253]
miR-let-7	Yes	No	Early tumor progression	Poor survival	Tissue	[241]
miR-221	Yes	Yes	Stages I–IV	Decreased OS	Serum	[254]
miR-21	Yes	Yes	Stages I–IV	OS	Serum	[255]
miR-335	Yes	No	Distant metastasis (stages III/IV)	OS and RFS	Tissue	[256]
miR-429	Yes	Yes	Stages III-IV	OS	Serum	[168]
miR-199a	Yes	Yes	Stages III-IV	Poor OS		[257]
miR-1246	No	Yes	Stages III-IV	—	Serum	[258]

PFS: progression-free survival, OS: overall survival, RFS: recurrence-free survival.